Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: Case report and review of the literature

Pharmacotherapy

Volumn 25, Issue 10 I, 2005, Pages 1389-1395

  Bickford, Courtney L ^a   Spencer, Anne P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Biliary sludge; Ceftriaxone; Hyperbilirubinemia

Indexed keywords

BILIRUBIN; CEFTRIAXONE;

ADULT; BILIARY SLUDGE; BILIARY TRACT DISEASE; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHOLELITHIASIS; DRUG WITHDRAWAL; ECHOGRAPHY; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; LIVER FUNCTION TEST; MALE; MENINGITIS; PEDIATRICS; PNEUMONIA; REVIEW;

ANTI-BACTERIAL AGENTS; BILE; CEFTRIAXONE; HUMANS; HYPERBILIRUBINEMIA; MALE; MIDDLE AGED;

EID: 26044460539     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.10.1389     Document Type: Review

References (46)

1. Ko CW, Sekijima JH, Lee SP. Biliary sludge. Ann Intern Med 1999;130(4):301-11.
2. Shaffer EA. Gallbladder sludge: what is its clinical significance? Curr Gastroenterol Rep 2001;3:166-73.
3. Famularo G, Polchi S, De Simone C. Acute cholecystitis and pancreatitis in a patient with biliary sludge associated with the use of ceftriaxone: a rare but potentially severe complication. Ann Ital Med Int 1999;14:202-4.
4. Ahmed M, Cheung RC, Keeffe EB, Ahmed A. Differential diagnosis of gallstone-induced complications. South Med J 2000;93:261-4.
5. Ahmed M, Cheung RC, Keeffe EB. Management of gallstones and their complications. Am Fam Physician 2000;61:1673-80.
6. Lee SP, Lipsky BA, Teefey SA. Gallbladder sludge and antibiotics. Pediatr Infect Dis J 1990;9:422-3.
7. Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge: identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology 1991;100:1665-70.
8. Shiffman M, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge: in vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 1990;99:1772-8.
9. Roche Pharmaceuticals. Rocephin (ceftriaxone) package insert. Nutley, NJ; 2004.
10. Schaad UB, Tschappeler H, Lentze MJ. Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy. Pediatr Infect Dis 1986;5:708-10.
11. Kim YS, Kestell MF, Lee SP. Gall-bladder sludge: lessons from ceftriaxone. J Gastroenterol Hepatol 1992;7:618-21.
12. Michielsen PP, Fierens H, Van Maercke YM. Drug-induced gallbladder disease: incidence, aetiology and management. Drug Saf 1992;7:32-45.
13. Papadopoulou F, Efremidis S, Karyda S, et al. Incidence of ceftriaxone-associated gallbladder pseudolithiasis. Acta Paediatr 1999;88:1352-5.
14. Schaad UB, Wedgewood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet 1988:2(8625):1411-13.
15. Schaad UB, Suter S, Gianella-Borradori A, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990;322:141-7.
16. Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM. Ceftriaxone-associated biliary pseudolithiasis in adults. Lancet 1989;2(8655):165.
17. Stabile A, Ferrara P, Marietti G, Maresca G. Ceftriaxone-associated gallbladder lithiasis in children [letter]. Eur J Pediatr 1995;154:590.
18. Lopez AJ, O'Keefe P, Morrisey M, Pickleman J. Ceftriaxone-induced cholelithiasis. Ann Intern Med 1991;115(9):712-14.
19. Meyboom RH, Kuiper H, Jansen A. Ceftriaxone and reversible cholelithiasis. BMJ 1988;297:858.
20. Zinberg J, Chernaik R, Coman E, Rosenblatt R, Brandt LJ. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis. Am J Gastroenterol 1991;86: 1251-4.
21. Cometta A, Gallot-Lavallee-Villars S, Iten A, et al. Incidence of gallbladder lithiasis after ceftriaxone treatment. J Antimicrob Chemother 1990;25:689-95.
22. Heim-Duthoy KL, Caperton EM, Pollock R, Matzke GR, Enthoven D, Peterson PK. Apparent biliary pseudolithiasis during ceftriaxone therapy. Antimicrob Agents Chemother 1990;34:1146-9.
23. Acun C, Erdem LO, Sogut A, Erdem CZ, Tomac N, Gundogdu S. Ceftriaxone-induced biliary pseudolithiasis and urinary bladder sludge. Pediatr Int 2004;46:368-70.
24. Biais C, Duperval R. Biliary pseudolithiasis in a child associated with 2 days of ceftriaxone therapy. Pediatr Radiol 1994;24:218-19.
25. De Moor RA, Egberts ACG, Schrode CH. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr 1999;158:975-7.
26. Herek O, Sarioglu A, Kocer N, Tiraki A, Akkemik B. Biliary pseudolithiasis in childhood: a case report. Eur J Pediatr Surg 1999;9:337-9.
27. Maranan MC, Gerber SI, Miller GG. Gallstone pancreatitis caused by ceftriaxone. Pediatr Infect Dis J 1998;17:662-3.
28. Prince JS, Senac MO. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child. Pediatr Radiol 2003;33:648-51.
29. Robertson FM, Crombleholme TM, Barlow SE, Verhave M, Brown D. Ceftriaxone choledocholithiasis. Pediatrics 1996;98:133-5.
30. Acun C, Erdem LO, Sogut A, et al. Gallbladder and urinary tract precipitations associated with ceftriaxone therapy in children: a prospective study. Ann Trop Paediatr 2004;24: 25-31.
31. Bonnet JP, Abid L, Dabhar A, Levy A, Soulier Y, Blangy S. Early biliary pseudolithiasis during ceftriaxone therapy for acute pyelonephritis in children: a prospective study in 34 children. Eur J Pediatr Surg 2000;10:368-71.
32. Ettestad PJ, Campbell GL, Welbel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis 1995;171:356-61.
33. Van Reempts PJ, Van Overmeire B, Mahieu LM, Vanacker KJ. Clinical experience with ceftriaxone treatment in the neonate. Chemotherapy 1995;41:316-22.
34. Bor O, Dinleyici EC, Kebapci M, Aydogdu SD. Ceftriaxone-associated biliary sludge and pseudocholelithiasis during childhood: a prospective study. Pediatr Int 2004;46:322-4.
35. Oakes M, MacDonald H, Wilson D. Abnormal laboratory test values during ceftriaxone therapy. Am J Med 1984;77(4C): 89-96.
36. Moskovitz BL. Clinical adverse effects during ceftriaxone therapy. Am J Med 1984;77(4C):84-8.
37. Barson WJ, Miller MA, Brady MT, Powell DA. Prospective comparative trial of ceftriaxone vs. conventional therapy for treatment of bacterial meningitis in children. Pediatr Infect Dis 1985;4:362-8.
38. Fink S, Karp W, Robertson A. Ceftriaxone effect on bilirubin-albumin binding. Pediatrics 1987;80:873-5.
39. Wadsworth SJ, Suh B. In vitro displacement of bilirubin by antibiotics and 2-hydroxybenzoylglycine in newborns. Antimicrob Agents Chemother 1988;32:1571-5.
40. Gulian JM, Dalmasso C, Pontier F, Gonard V. Displacement effect of ceftriaxone on bilirubin bound to human serum albumin. Chemotherapy 1986;32:399-403.
41. Gulian JM, Gonard V, Dalmasso C, Palix C. Bilirubin displacement by ceftriaxone in neonates: evaluation by determination of 'free' bilirubin and erythrocyte-bound bilirubin. J Antimicrob Chemother 1987;19:823-9.
42. Gulian JM, Dalmasso C, Gonard V. Interaction of beta-lactam antibiotics on bilirubin-albumin complex: comparison by three methods, total bilirubin, unbound bilirubin and erythrocyte-bound bilirubin. Chemotherapy 1990;36:91-7.
43. Brodersen R, Robertson A. Ceftriaxone binding to human serum albumin: competition with bilirubin. Mol Pharmacol 1989;36:478-83.
44. Martin E, Fanconi S, Kalin P, et al. Ceftriaxone-bilirubin-albumin interactions in the neonate: an in vivo study. Eur J Pediatr 1993;152:530-4.
45. Robertson A, Fink S, Karp W. Effect of cephalosporins on bilirubin-albumin binding. J Pediatr 1988;112:291-4.
46. Centers for Disease Control and Prevention. Ceftriaxone-associated biliary complications of treatment of suspected disseminated Lyme disease. MMWR Morb Mortal Wkly Rep 1993;42:39-42.